1. Introduction {#sec1}
===============

Upper urinary tract urothelial carcinoma (UTUC) accounts for 10% of renal tumors and 5% of all urothelial malignancies \[[@B1], [@B2]\]. Radical nephroureterectomy (RNU) with the removal of the bladder cuff is the standard treatment of UTUC, including high-risk noninvasive and invasive UTUC \[[@B3], [@B4]\]. The incidence of invasive UTUC (approximately 60%) is much higher than that of bladder cancer. The prognosis of UTUC is poor worldwide, with a recurrence rate ranging from 30% to 75% \[[@B2], [@B5]\]. Therefore, an exploration of the potential prognostic factors in UTUC is important for risk classification. Many studies have indicated that older age, a history of bladder cancer, a higher tumor stage, a higher tumor grade, lymph node metastasis, multifocality, and hydronephrosis are predictors of disease recurrence or survival \[[@B1], [@B5], [@B6]\].

Lymphovascular invasion (LVI) is defined as the invasion of tumor cells into an endothelium-lined space of vascular or lymphatic vessels without underlying muscular walls \[[@B7]\]. The process of LVI is a crucial phase in the systemic dissemination of cancer cells \[[@B8]\]. In cancers of the liver, testis, and penis \[[@B9]\], LVI is included in the American Joint Committee on Cancer (AJCC) tumor, node, metastasis (TNM) staging criteria for higher-risk patients, indicating that LVI might have a similar significance in the TNM classification. Many studies have estimated the prognostic influence of LVI in patients with UTUC, but the results remain controversial \[[@B10]--[@B36]\]. The European Association of Urology Guidelines indicate that LVI is an independent prognostic predictor of UTUC based on two retrospective studies \[[@B1]\]. One recent meta-analysis analyzed the prognostic value of LVI in UTUC but showed high heterogeneity \[[@B37]\]. Considering the new articles published in the past 5 years, we aimed to develop more stringent inclusion and exclusion criteria with which to further validate the prognostic impact of LVI on UTUC and explore the potential factors causing heterogeneity.

2. Methods {#sec2}
==========

2.1. Literature Search {#sec2.1}
----------------------

We searched several electronic databases (PubMed, Embase, Web of Science, and the Cochrane Library) for relevant studies up to 31 December 2018. The following search terms were used to identify studies focusing on the prognostic value of LVI in UTUC: (1) "upper urinary tract" and "carcinoma" or "cancer" and "lymphovascular invasion"; (2) "upper urinary tract" and "carcinoma" or "cancer" and "survival" or "Cox" or "multivariable."

2.2. Study Selection {#sec2.2}
--------------------

We defined the inclusion and exclusion criteria before searching for articles. Studies were included if they met the following criteria: (1) the study evaluated LVI as a prognostic factor in patients with UTUC after RNU; (2) the study reported adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) of progression-free survival (PFS), cancer-specific survival (CSS), or overall survival (OS) in a multivariate analysis with Cox proportional hazard regression; and (3) the study was published in English. The exclusion criteria were as follows: (1) the study did not provide sufficient data to acquire the HR and its standard error, (2) the article described a review or study on cell lines or animal models, (3) the number of cases was \<100, (4) surgical treatment was not limited to RNU, and (5) neoadjuvant chemotherapy was applied to the participants. When more than one article was based on the same study population, we included the most complete or the most recent study.

2.3. Endpoints and Data Extraction {#sec2.3}
----------------------------------

The endpoints of our study were PFS, CSS, and OS. Disease recurrence was defined as local failure or distant metastasis after surgery. CSS included only patients who died of UTUC, and OS included all causes of deaths. The extracted items were as follows: first author, publication year, region, recruitment period, number of cases, definition of LVI, LVI percentage, inclusion and exclusion criteria, definition of recurrence, and adjusted covariates (age, sex, operation, tumor location, lymph node status, history of bladder cancer, adjuvant chemotherapy, primary tumor stage, tumor grade, carcinoma *in situ*, margin status, hydronephrosis, multifocality, tumor architecture, body mass index, and adjusted HR with 95% CI of PFS, CSS, and OS). Two reviewers investigated relevant articles and extracted data, respectively. Disagreements between the two reviewers regarding data abstraction were resolved through discussion.

2.4. Statistical Analysis {#sec2.4}
-------------------------

The effect measures for the outcomes of PFS, CSS, and OS were the HRs and 95% CIs in the multivariable analysis with Cox proportional hazard regression, which were extracted from all included studies. LVI was considered an independent predictor if the pooled 95% CI did not overlap with 1 and *P* \< 0.05. The *I*^2^ statistic (total percentage of variation resulting from heterogeneity) was calculated to quantify the degree of heterogeneity. A fixed effects model was adopted to pool the HRs if *I*^2^ was ≤50%; otherwise, a random effects model was selected. We performed a subgroup analysis and a meta-regression analysis to explore potential heterogeneity. Next, a Galbraith plot was designed and a leave-one-out analysis was performed to search for studies causing heterogeneity and examine the weight of their influence on the pooled HR \[[@B38]\]. An influence analysis, in which one study was omitted and then the remaining studies were recalculated, was conducted to confirm the stability of the results. Publication bias was estimated by Egger\'s linear regression and funnel plot. All reported *P* values were two-sided, and the statistical significance was set at *P* ≤ 0.05. Statistical analysis was performed using Stata version 15.0 (Stata Corp., College Station, TX).

3. Results {#sec3}
==========

3.1. Study Selection {#sec3.1}
--------------------

The process of identifying relevant studies is illustrated in [Figure 1](#fig1){ref-type="fig"}. In total, 2985 articles were obtained from PubMed, Embase, and the Cochrane Library. After excluding 852 duplicate articles, we read 2133 titles and abstracts for further screening. Based on the information obtained from 291 original articles, 56 studies were excluded due to the presence of identical cohorts. Finally, 27 articles were included in this study to explore the prognostic value of LVI in UTUC \[[@B10]--[@B36]\], among which 4 articles analyzed LVI as a survival predictor in patients with advanced tumor stages (T3--T4) \[[@B10], [@B13], [@B16], [@B26]\].

3.2. Study Characteristics {#sec3.2}
--------------------------

Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"} summarize the characteristics of the 27 eligible studies. These 27 retrospective studies involved a total of 17,453 patients, with a wide recruitment period from 1987 to 2016. The number of male and female participants was 10,418 and 5320, respectively. Among the 27 studies, 9 assessed patients from Japan, 7 from China, 5 from Korea, 4 from Europe, and 2 from multiple countries. In total, 4217 patients with positive LVI were enrolled in our study, and the overall proportion of LVI was 24.2%. Studies including fewer than 100 patients were removed to limit heterogeneity; thus, the sample size of the enrolled studies ranged from 109 to 2492. Bladder recurrence was not considered a disease recurrence except in one study \[[@B18]\]. Twenty-two studies were adjusted for more than four covariates, and all studies adjusted for the effect of tumor stage and/or grade in the multivariable analysis.

3.3. Prognostic Value of LVI in UTUC {#sec3.3}
------------------------------------

When *I*^2^ \> 50%, we used a random effects model to pool the HRs. The pooled HR was statistically significant for PFS (HR = 1.73, 95%CI = 1.41--2.11), CSS (HR = 1.87, 95%CI = 1.54--2.27), and OS (HR = 1.56, 95%CI = 1.29--1.87), with high heterogeneity (*I*^2^ = 77.8%, 70.3%, and 59.2%, respectively) (shown in Figures [2(a)](#fig2){ref-type="fig"}--[2(c)](#fig2){ref-type="fig"}). Four studies explored the prognostic influence of LVI in patients with advanced tumor stages (T3--T4). Through the fixed effects model (*I*^2^ = 33.9%), the pooled HR was 1.64 (95%CI = 1.35--1.99) for CSS ([Figure 2(d)](#fig2){ref-type="fig"}). We encompassed 6 studies that analyzed LVI as a survival predictor restricted to patients without lymph node metastasis and to those who have not undergone lymphadenectomy \[[@B16], [@B35], [@B39]--[@B42]\]. LVI was positively associated with the higher risk of disease recurrence (PFS: HR = 2.17, 95%CI = 1.73--2.73) and cancer-specific mortality (CSS: HR = 2.13, 95%CI = 1.66--2.73), without heterogeneity (both *I*^2^ = 0%) (Figures [3(a)](#fig3){ref-type="fig"} and [3(b)](#fig3){ref-type="fig"}).

3.4. Subgroup Analysis and Sensitivity Analysis {#sec3.4}
-----------------------------------------------

To explore the source of potential heterogeneity, we classified the enrolled studies into those from Japan, Korea, China, and other regions (two from France, two from multiple regions, one from Germany, and one from Serbia). In PFS and CSS, the *I*^2^ value decreased in groups of Japan, South Korea, and China ([Table 3](#tab3){ref-type="table"}). The metaregression analysis showed that the performance of the studies in different regions might have been the origin of potential heterogeneity in PFS (*P* = 0.055) and CSS (*P* = 0.011). The Galbraith plot showed that one study revealed heterogeneity in OS ([Figure 4](#fig4){ref-type="fig"}); in the leave-one-out analysis, the heterogeneity decreased to 0.0% after excluding this study \[[@B22]\]. The sensitivity analysis showed that the pooled HRs of PFS, CSS, and OS were stable and that none of the studies could powerfully change the positive outcome. After omitting four studies in PFS and three in CSS by the leave-one-out analysis, a stable positive result (PFS: HR = 1.84, 95%CI = 1.65--2.06; CSS: HR = 2.23, 95%CI = 1.97--2.53) indicated the prognostic value of LVI in UTUC, with low heterogeneity (PFS: *I*^2^ = 4.4%; CSS: *I*^2^ = 2.2%).

3.5. Publication Bias {#sec3.5}
---------------------

Egger\'s plot showed no significant evidence of publication bias for any of the three outcomes (PFS: *P* = 0.443, CSS: *P* = 0.096, and OS: *P* = 0.894) (Figures [5(a)](#fig5){ref-type="fig"}--[5(c)](#fig5){ref-type="fig"}). Likewise, the funnel plots showed no significant evidence of publication bias (data not shown).

4. Discussion {#sec4}
=============

Because of the poor prognosis of UTUC, it is necessary to identify high-risk patients for individual therapy. LVI is included in the AJCC TNM staging criteria for cancers of the liver, testis, and penis \[[@B9]\]; in these staging criteria, LVI can upstage the cancer. Although LVI was shown to increase the prognostic risk of UTUC in many studies \[[@B29]--[@B33]\], it is not required for stage grouping in the AJCC cancer staging manual. The present study builds on a previous meta-analysis by including recently published studies that focus on the prognostic impact of LVI on UTUC \[[@B37]\]. Using more stringent inclusion and exclusion criteria, we aimed to further validate the prognostic risk of LVI and explore the potential factors causing heterogeneity.

In this meta-analysis, we identified 18 studies evaluating PFS, 19 evaluating CSS, 11 evaluating OS, 4 evaluating the CSS of patients with advanced tumor stages, and 6 evaluating the PFS and CSS in node-negative patients. Given the rarity of UTUC, it is notable that the present meta-analysis has a higher sample size than that of a previously published meta-analysis \[[@B37]\] and has the largest amount of data. Compared with patients with UTUC and no LVI, patients with concurrent UTUC and LVI had a 1.73-fold higher risk of developing disease recurrence (HR = 1.73, 95%CI = 1.41--2.11) and a 1.87-fold higher risk of cancer-specific death (HR = 1.87, 95%CI = 1.54--2.27), suggesting that LVI is an independent prognostic predictor in patients with UTUC. These results are congruent with those of a previous meta-analysis that reported a positive association of LVI with oncologic outcomes, with a pooled HR of 1.91 and 1.72 for PFS and CSS, respectively \[[@B37]\]. Ku et al. did not prove that LVI was an independent factor in UTUC based on two studies (HR = 4.05, 95%CI = −0.44 to 8.53) \[[@B37]\]. However, LVI was evaluated as a strong predictor of poor OS in patients with UTUC (HR = 1.56, 95%CI = 1.29--1.87) through pooling of 11 studies. Only four studies explored the prognostic value of LVI in patients with advanced tumor stages (T3--T4). Through our fixed effects model (*I*^2^ = 33.9%), the pooled HR showed that LVI could increase the risk of cancer-specific death (HR = 1.64, 95%CI = 1.35--1.99). Unfortunately, most articles did not investigate the relationship between LVI and different stages of UTUC; thus, adding LVI as a predictor to TNM staging requires studies that focus on stratification of the tumor stage. Novara et al. have investigated the interaction between LVI and lymph node stage \[[@B40]\]. They found that LVI was associated with PFS and CSS in patients with negative lymph nodes, not in lymph node-positive patients. In our study, we revealed that the presence of LVI increased the risk of both disease recurrence and cancer-specific mortality in patients with pN0 and pNx disease (HR = 2.17 and 2.13, respectively). There was no sufficient data for us to explore the effect of LVI on node-positive patients. LVI was an essential and important step in the systemic dissemination of cancer cells \[[@B40]\]. Although lymph node metastasis at the time of RNU could be a reliable prognostic predictor of recurrence, no standard guideline for the appropriate area of lymphadenectomy during RNU has been established \[[@B35]\]. Therefore, LVI could identify patients without lymph node involvement or undergoing lymph node resection who are at an increased risk of cancer recurrence and mortality. Our study represents a more comprehensive analysis of the effect of LVI on UTUC and prompts both urologists and oncologists to select patients at a higher risk of recurrence or death because such patients may be candidates for further therapy (adjuvant chemotherapy) or more intense follow-up. On this basis, pathologists should routinely perform an exhaustive pathological assessment of UTUC specimens to identify LVI \[[@B43]\].

We developed more stringent exclusion criteria and conducted a subgroup analysis to decrease the clinical heterogeneity. Studies with fewer than 100 patients were excluded to rule out interference with the outcomes \[[@B43]\]. Studies that included neoadjuvant chemotherapy or conservative surgery, such as segmental ureterectomy with termino-terminal anastomosis, were omitted to maintain the analysis of only a single treatment (RNU) with adjuvant chemotherapy. The utility of neoadjuvant chemotherapy in patients with UTUC remains uncertain, and additional trials are thus needed; however, adjuvant chemotherapy can increase CSS and OS in patients with UTUC \[[@B44]\]. After the studies had been classified by region, the heterogeneity of PFS and CSS was significantly reduced except in China. For further analysis, we designed a Galbraith plot and performed a leave-one-out analysis and identified one study from China causing heterogeneity in all three outcomes \[[@B22]\]. This might have been due to the low percentage (11%) of LVI, which was diagnosed depending on the level of pathologists. Nonetheless, the pooled HRs of each group in the three outcomes were still positive, excluding the study from China; therefore, we considered that LVI was an independent prognostic predictor in UTUC despite the high heterogeneity. There was no heterogeneity between LVI and lymph node-negative patients, indicating the strongly predictive value of LVI on them.

The biological mechanisms of the positive association between LVI and poor UTUC outcomes are complex. LVI is defined as the presence of tumor cells within an endothelium-lined space without underlying muscular walls \[[@B7]\] and is an important step in tumor dissemination. Tumor cells enter the circulation through the lymphatic and blood vessels, forming micrometastases \[[@B45]\]. Additionally, LVI has been linked with lymph node involvement and is suggested to be a prerequisite for lymph node invasion \[[@B35], [@B40], [@B45]\]. Lymph node metastasis is included in the TNM classification. More importantly, the presence of LVI is associated with disease recurrence or mortality in patients with node-negative UTUC, but not in those with node-positive UTUC \[[@B40], [@B45]\]. Moreover, LVI significantly increases the risk of disease recurrence, cancer-specific mortality, and overall mortality after effective local treatment (RNU). Based on these above-described factors, LVI is considered to play an important role in the metastatic process and promote a poor prognosis \[[@B45]\].

To the best of our knowledge, this meta-analysis is the most comprehensive of its kind to identify the association between LVI and poor outcomes of UTUC. This meta-analysis has several strengths. First, we adopted the largest sample size (17,453 patients), although we used more stringent inclusion and exclusion criteria. This massive study population enhances the statistical power and ensures more accurate risk estimation. Second, this is the first analysis of the influence of LVI in patients with advanced tumor stages (T3--T4) and lymph node-negative UTUC through a meta-analysis with low heterogeneity. Third, no publication bias existed in our study. Our meta-analysis also had several limitations. First, all enrolled articles were retrospective studies; thus, many confounding factors could not be corrected because of a lack of patient information. For this reason, the outcomes of our meta-analysis might deviate from the actual situation in the clinical setting. Second, significant heterogeneity was found for PFS, CSS, and OS. However, we found the potential origin of heterogeneity and the article causing heterogeneity through subgroup, meta-regression, and leave-one-out analyses. After excluding the article from China, the *I*^2^ of PFS, CSS, and OS decreased to 68%, 58%, and 0%, respectively. The heterogeneity mainly came from the geographical region (for PFS and CSS). Although a random effects model was used and many statistical methods were implemented, the conclusions reached in our meta-analysis should be interpreted with caution.

5. Conclusions {#sec5}
==============

In conclusion, the pooled results demonstrate that LVI is a significant prognostic factor for UTUC, especially for lymph node-negative patients, and is strongly associated with disease recurrence, cancer-specific mortality, and overall mortality. It can also denote a poor prognosis of UTUC with an advanced tumor stage (T3--T4). We advocate systematic assessment of LVI after RNU using pathological specimens. The results of this meta-analysis need to be further confirmed by adequately designed prospective studies before LVI is included in the AJCC TNM staging system of UTUC.

This study was partly funded by the National Natural Science Foundation of China (Grant Nos. NSFC 81502195 and 81672512) and the Health Science Technology Development Project of Shandong Province (Grant No. 2016WS0258). We thank Angela Morben, DVM, ELS, from Liwen Bianji, Edanz Editing, China (<http://www.liwenbianji.cn/ac>), for editing the English text of a draft of this manuscript.

Conflicts of Interest
=====================

The authors declare that there is no conflict of interest regarding the publication of this article.

![Flow chart for the identification of relevant articles.](DM2019-7386140.001){#fig1}

![Forest plots of hazard ratios (HRs) for the association between lymphovascular invasion and upper urinary tract urothelial carcinoma. (a) Progression-free survival (PFS). (b) Cancer-specific survival (CSS). (c) Overall survival (OS). (d) Lymphovascular invasion and CSS in patients with advanced tumor stages (T3--T4).](DM2019-7386140.002){#fig2}

![Forest plots of hazard ratios (HRs) for the association between lymphovascular invasion and upper urinary tract urothelial carcinoma in node-negative patients. (a) Progression-free survival (PFS). (b) Cancer-specific survival (CSS).](DM2019-7386140.003){#fig3}

![Galbraith plot showing the potential heterogeneity for overall survival. b: regression coefficient; SE: standard error.](DM2019-7386140.004){#fig4}

![Egger\'s funnel plots for publication bias. (a) Progression-free survival (PFS). (b) Cancer-specific survival (CSS). (c) Overall survival (OS). SND: standard normal deviate; CI: confidence interval.](DM2019-7386140.005){#fig5}

###### 

Characteristics of studies included in meta-analysis.

  Study   Author             Country         Multicenter   No. of cases   Recruitment period   Exclude BC patients   Definition of LVI   No. of positive LVI (%)   Age (year)     Gender (male/female)   Definition of recurrence
  ------- ------------------ --------------- ------------- -------------- -------------------- --------------------- ------------------- ------------------------- -------------- ---------------------- ------------------------------
  2018    Ikeda et al.       Japan           Yes           441            1990-2015            No                    Yes                 156 (37)                  69.0 (62-75)   319/122                Excluding bladder recurrence
  2018    Kohada et al.      Japan           No            148            1999-2016            No                    No                  55 (37)                   71.0 (64-78)   112/36                 Excluding bladder recurrence
  2018    Abe et al.         Japan           Yes           214            2000-2015            Yes                   No                  96 (45)                   70.5 (35-93)   151/63                 Excluding bladder recurrence
  2018    Kim et al.         Korea           Yes           1521           2000-2012            Yes                   No                  332 (22)                  65.0 (57-72)   1127/394               Excluding bladder recurrence
  2018    Tan et al.         China           No            710            2013-2016            No                    No                  99 (15)                   65.8           380/288                Excluding bladder recurrence
  2018    Kim et al.         Korea           Yes           1276           2000-2012            Yes                   No                  258 (20)                  65.7           941/335                Excluding bladder recurrence
  2017    Huang et al.       China           No            481            2003-2013            Yes                   No                  76 (16)                   65.8 (30-89)   311/170                NA
  2017    Nakagawa et al.    Japan           Yes           109            1996-2013            Yes                   No                  78 (72)                   71.0 (64-77)   67/42                  Excluding bladder recurrence
  2017    Cho et al.         Korea           Yes           1049           2004-2015            Yes                   No                  202 (19)                  68.5           759/290                Including bladder recurrence
  2016    Tai et al.         China           No            503            1996-2009            Yes                   No                  87 (18)                   68.7 (59-75)   249/234                Excluding bladder recurrence
  2016    Shibing et al.     China           Yes           795            2002-2012            Yes                   Yes                 84 (11)                   NA             462/333                Excluding bladder recurrence
  2016    Song et al.        China           No            140            2005-2011            Yes                   No                  6 (4)                     NA             86/54                  Excluding bladder recurrence
  2016    Kobayashi et al.   Japan           Yes           839            1990-2011            Yes                   Yes                 326 (39)                  70.4 (63-78)   610/229                Excluding bladder recurrence
  2016    Waseda et al.      Japan           Yes           1068           1995-2013            Yes                   No                  446 (42)                  70.0 (62-76)   758/310                Excluding bladder recurrence
  2016    Mbeutcha et al.    International   Yes           716            1990-2008            No                    No                  149 (21)                  70.0 (63-76)   400/316                NA
  2016    Kim et al.         Korea           No            371            1992-2012            Yes                   Yes                 71 (19)                   64.7           287/84                 NA
  2016    Matsumoto et al.   Japan           No            144            1995-2010            No                    No                  93 (65)                   71.0 (14-98)   104/40                 NA
  2015    Hara et al.        Japan           Yes           1172           2005-2011            No                    Yes                 423 (36)                  71.0 (21-97)   806/366                Excluding bladder recurrence
  2015    Tanaka et al.      Japan           Yes           394            1995-2011            Yes                   Yes                 170 (43.1)                70.0           289/105                Excluding bladder recurrence
  2015    Lee et al.         China           No            250            2004-2010            Yes                   Yes                 60 (24)                   NA             108/142                Excluding bladder recurrence
  2015    Kang et al.        Korea           Yes           440            2001-2013            Yes                   No                  76 (17)                   NA             305/135                Excluding bladder recurrence
  2015    Milojevic et al.   Serbia          No            238            1999-2013            Yes                   No                  154 (65)                  66.5           132/106                Excluding bladder recurrence
  2014    Aziz et al.        Germany         No            256            1990-2012            Yes                   Yes                 52 (20)                   68.6           169/96                 Excluding bladder recurrence
  2013    Liu et al.         China           Yes           421            1999-2010            Yes                   Yes                 101 (24)                  NA             285/136                NA
  2013    Hurel et al.       France          Yes           551            1995-2010            Yes                   Yes                 163 (30)                  69.4           365/188                Excluding bladder recurrence
  2013    Ouzzane et al.     France          Yes           714            1995-2010            Yes                   No                  157 (22)                  70.0           484/228                Excluding bladder recurrence
  2012    Chromecki et al.   International   Yes           2492           1987-2007            Yes                   Yes                 247 (10)                  69.2           1681/811               Excluding bladder recurrence

NA: not available; BC: bladder cancer; LVI: lymphovascular invasion.

###### 

Outcomes of studies included in meta-analysis.

  Year   Author             PFS HR (95% CI)        CSS HR (95% CI)        OS HR (95% CI)       No. of covariates   Adjusted variables (part)
  ------ ------------------ ---------------------- ---------------------- -------------------- ------------------- -------------------------------------------------------------------------------------------------------------
  2018   Ikeda et al.       2.51 (1.552-4.07)      3.5 (1.954-6.259)      NA                   11                  Age, gender, tumor location, pN, history of BC, adjuvant therapy, pT, tumor grade, CIS, tumor architecture
  2018   Kohada et al.      2.65 (1.52-4.67)       2.62 (1.06-6.96)       NA                   5                   pT, tumor grade, hydronephrosis
  2018   Abe et al.         1.162 (0.647-2.133)    2.11 (0.988-4.839)     1.326 (0.697-2.52)   3                   pN, pT, tumor grade
  2018   Kim et al.         1.76 (1.4-2.21)        1.9 (1.49-2.44)        1.85 (1.48-2.31)     14                  Age, gender, operation, tumor location, pN, history of BC, adjuvant therapy, pT, tumor grade, CIS, BMI
  2018   Tan et al.         1.02 (0.73-1.43)       1.16 (0.79-1.7)        1.16 (0.82-1.65)     14                  Age, gender, tumor location, pN, adjuvant therapy, pT, tumor grade, tumor architecture, multifocality
  2018   Kim et al.         1.859 (1.464-2.36)     1.829 (1.43-2.338)     1.776 (1.36-2.32)    8                   Tumor grade, tumor architecture, margin status, pN
  2017   Huang et al.       NA                     1.72 (1.14-2.59)       1.51 (1.04-2.2)      6                   Age, pN, pT, tumor grade, multifocality
  2017   Nakagawa et al.    2.02 (0.85-5.61)       3.02 (0.76-20.43)      NA                   5                   Age, adjuvant therapy, tumor grade, hydronephrosis
  2017   Cho et al.         1.69 (1.37-2.09)       2.78 (1.88-4.1)        1.98 (1.42-2.77)     19                  Age, gender, operation, tumor location, pN, history of BC, pT, CIS, hydronephrosis, multifocality, BMI
  2016   Tai et al.         1.05 (0.56-1.95)       NA                     NA                   3                   Tumor location, pT, tumor grade
  2016   Shibing et al.     0.802 (0.6-1.072)      0.909 (0.68-1.215)     0.913 (0.695-1.2)    10                  Age, operation, tumor location, pN, pT, tumor grade, tumor architecture
  2016   Song et al.        3.165 (0.487-20.565)   4.898 (0.563-42.626)   NA                   15                  Age, gender, tumor location, history of BC, pT, tumor grade, hydronephrosis
  2016   Kobayashi et al.   2.02 (1.46-2.8)        2.28 (1.55-3.36)       NA                   6                   Age, gender, pN, adjuvant therapy, pT, tumor grade
  2016   Waseda et al.      2.7 (1.97-3.69)        2.83 (1.95-4.1)        NA                   5                   Age, tumor location, pN, pT, tumor grade
  2016   Mbeutcha et al.    NA                     1.23 (0.83-1.81)       1.35 (0.98-1.87)     12                  Age, gender, tumor location, pN, history of BC, adjuvant therapy, pT, tumor grade, CIS, tumor architecture
  2016   Matsumoto et al.   1.88 (0.73-5.03)       1.32 (0.46-3.82)       1.07 (0.44-2.61)     6                   pT, tumor grade
  2016   Kim et al.         NA                     1.82 (0.99-3.32)       NA                   3                   Tumor location, history of BC, tumor grade
  2015   Tanaka et al.      NA                     NA                     1.67 (1.01-2.74)     4                   Age, adjuvant therapy, pT, tumor grade
  2015   Hara et al.        3.19 (2.09-4.87)       NA                     NA                   16                  Age, gender, operation, tumor location, pN, history of BC, adjuvant therapy, pT, tumor grade, margin status
  2015   Lee et al.         1.71 (1-2.93)          1.38 (0.69-2.75)       NA                   4                   pN, pT, tumor grade
  2015   Kang et al.        NA                     3.097 (1.81-5.297)     2.4 (1.469-3.921)    9                   Age, adjuvant therapy, pT, tumor grade, margin status, multifocality, adjuvant therapy, BMI
  2015   Milojevic et al.   0.58 (0.32-1.07)       NA                     NA                   5                   pN, history of BC, adjuvant therapy, pT, tumor grade
  2014   Aziz et al.        2.7 (1.59-4.57)        2.5 (1.45-4.3)         1.91 (1.22-2.98)     10                  Age, tumor location, pN, pT, tumor grade, tumor architecture, multifocality
  2013   Liu et al.         NA                     1.16 (0.818-1.645)     NA                   13                  Age, gender, operation, tumor location, pN, adjuvant therapy, pT, tumor grade, margin status, multifocality
  2013   Hurel et al.       2.14 (1.38-3.3)        1.73 (1.01-2.95)       NA                   8                   Age, tumor location, pN, adjuvant therapy, pT, tumor grade, margin status
  2013   Ouzzane et al.     NA                     NA                     1.57 (1.03-2.4)      6                   Age, tumor location, pN, pT, tumor grade, margin status
  2012   Chromecki et al.   1.31 (1.1-1.57)        1.41 (1.16-1.72)       NA                   10                  Age, gender, tumor location, pN, adjuvant therapy, pT, tumor grade, tumor architecture, multifocality

NA: not available; BC: bladder cancer; PFS: progression-free survival; CSS: cancer-specific survival; OS: overall survival; HR: hazard ratio; CIS: carcinoma in situ; pT: pathological tumor stage; pN: pathological lymph node.

###### 

Subgroup analyses by region and meta-regression analyses for progression-free survival, cancer-specific survival, and overall survival.

  Region        No. of studies   Weight (%)   OR (95% CI)        *I* ^2^   *P* for heterogeneity   *P* ^∗^ for interaction
  ------------- ---------------- ------------ ------------------ --------- ----------------------- -------------------------
  PFS           18               100.00       1.73 (1.41-2.11)   77.8%     \<0.001                 0.055
   Japan        8                41.91        2.32 (1.90-2.83)   26.3%     0.219                   
   Korea        2                15.47        1.72 (1.47-2.01)   0.0%      0.798                   
   China        4                18.30        1.15 (0.72-1.84)   59.3%     0.061                   
   Others^a^    4                24.32        1.47 (0.89-2.43)   83.6%     \<0.001                 
  CSS           19               100.00       1.87 (1.54-2.27)   70.3%     \<0.001                 0.011
   Japan        7                28.60        2.57 (2.06-3.20)   0.0%      0.743                   
   Korea        3                19.89        2.40 (1.74-3.29)   53.3%     0.117                   
   China        5                25.94        1.25 (0.92-1.69)   51.2%     0.085                   
   Others ^a^   4                25.57        1.54 (1.20-1.97)   39.9%     0.172                   
  OS            11               100.00       1.56 (1.29-1.87)   59.2%     \<0.001                 0.636
   Japan        3                16.68        1.44 (1.01-2.07)   0.0%      0.661                   
   Korea        3                32.24        1.95 (1.64-2.31)   0.0%      0.635                   
   China        2                22.37        1.15 (0.71-1.89)   77.9%     0.033                   
   Others^a^    3                28.72        1.53 (1.23-1.92)   0.0%      0.463                   

^∗^ *P* values for meta-regression. ^a^Two studies from France, two from multiple countries, one from German, and one from Serbia. PFS: progression-free survival; CSS: cancer-specific survival; OS: overall survival.

[^1]: Academic Editor: Eric A. Singer
